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Chemotherapy and radiotherapy are the most 
effective anticancer modalities. However the effectiveness 
of chemotherapy, which targets DNA replication and 
mitosis, is limited by the side effects resulting from 
killing normal cells that proliferate. The discovery of 
molecular abnormities associated with neoplastic growth 
stimulated attempts to develop targeted therapies aimed 
at selectively inhibiting growth of cancer by interfering 
with specific molecules or signal transduction pathways 
that are over-expressed (overactive) in cancer cells. It 
was anticipated that targeted cancer therapies would be 
more effective than current treatments and less harmful to 
normal cells [1]. Imatinib mesylate (Gleevec, STI–571), 
the drug developed to treat Philadelphia chromosome 
positive CML, exemplifies the first successful application 
of targeted therapy [2].The success, however, is due 
to the fact that the target (Bcr-Abl tyrosine kinase) 
fulfils  two  criteria:  (i)  is  unique  to  this  leukemia  and 
not present in normal cells, and (ii) is essential for cell 
growth. Most other tumors do not express such unique 
features and therefore targeted treatments, especially of 
patients with most common solid tumors, has been less 
successful and is frequently disappointing [3]. This is not 
surprising because the target is usually the component 
of a cell signaling pathway that, while over-expressed in 
cancer, is essential for the  survival of cancer as well as 
normal cells. For example, if a cancer cell has e.g. 107 
-  and normal cell 103 – such cell signaling molecules, 
the treatment with the targeting inhibitor that inactivates 
99.99% of these molecules will completely deplete the 
normal cells but leave the cancer cells still with 103 
molecules. Thus, although the initial cancer response to 
the inhibitor may be quite dramatic, the escalation of dose 
and treatment duration is expected to lead to preferential 
killing of normal rather than cancer cells. Given the 
above, chemo- and radiotherapy are likely to remain the 
major therapeutic approaches in the armamentarium of 
oncologist for the near future. 
As mentioned, the side effects of chemotherapy limit 
its effectiveness. To overcome this limitation strategies 
designed to protect non-cancer cells during chemotherapy 
have been proposed. Since chemotherapeutic drugs target 
DNA replication (DNA damaging agents) or mitosis 
(mitotic blockers), strategies were aimed to combine 
chemotherapy with inhibitors that would halt progression 
of normal cells through the cell cycle, making them 
drug-resistant during the duration of their arrest [3-6].   
In most cancers the regulation of cell cycle progression 
is impaired, especially as a result of dysfunctional p53 
or retinoblastoma pathway. Therefore, the inhibitors 
targeting these pathways cannot effectively stop the 
cell cycle of cancer cells and therefore cannot offer 
protection to cancer cells. While such strategies, defined 
as  cyclotherapy  [5,6].  have  obvious  rationale,  their 
implementation in the clinic was difficult, being delayed 
by the need for extensive clinical trials of the cell cycle 
inhibitors (e.g. inhibitors of Cdks) as some of them may 
show toxicity. Furthermore, a highly balanced equilibrium 
between the protective- versus chemotherapeutic- agents, 
both in terms of their respective concentrations as well 
as the sequence of and length of administration, must be 
tested to achieve successful clinical application. 
In the current article in Oncotarget, Apontes et al 
[7] describe advances that move forward the potential 
clinical applications of cyclotherapy. The authors used 
mitotic inhibitors, paclitaxel and nocodazole as the 
chemotherapeutic agents designed to kill cancer cells. 
The strategy of normal cells protection relied on the use of 
either non-genotoxic inducer of p53, nutlin-3a (N-3a), the 
inhibitor of mTOR pathway rapamycin (RAPA), or the 
widely prescribed anti-diabetic drug, possibly affecting 
IGF-1 signaling, metformin (MF), each tested alone 
and in combination. Their data are very encouraging. 
Specifically, the authors have seen that N-3a, RAPA or 
MF, particularly when applied in combinations, halted 
cell cycle progression of the three normal human cell 
lines cells, arresting them reversibly in G1 and/or G2 and 
thereby protecting from the toxicity of mitotic inhibitors. 
No such arrest was observed in the case of breast cancer 
MDA-MB-231 cells having mutant p53. Of importance 
was the observation that the arrest of normal cells was 
achieved:  (i)  for  the  duration  equivalent  of  the  time Oncotarget 2011; 2:  107 - 108 108 www.impactjournals.com/oncotarget
interval during which the treatment of cancer cells with 
mitotic  inhibitors  (3  days)  eliminated  their  capability 
to proliferate (assessed 6 days later); and (ii) the arrest 
was to a large degree reversible and showed no evident 
toxicity. The maximal protective effects were seen in drug 
combinations such as N-3a+RAPA, N-3a+RAPA+MF, or 
RAPA+MF. Of further interest was the observation that 
while the protective effect of RAPA+MF for normal cells 
was seen at the reduced concentration of glucose such 
conditions were actually cytotoxic for cancer cells. The 
authors  offer  specific  recommendations  on  timing  and 
sequence  of  administration  of  protective  agents  versus 
mitotic inhibitors in treatment of cancer. 
Several implications advancing clinical use of 
cyclotherapy stem from the findings of Apontes et al.7 
One is that the protective agents MF and RAPA, albeit 
for different applications, are already widely used in the 
clinic. Therefore their toxicity and pharmacokinetics are 
well characterized. N-3a, while not advanced in clinical 
trials, appears to be mimicked in terms of its ability to 
activate  p53,  by  low  concentrations  of  actinomycin 
D   [6,8],  the  drug  whose  clinical  application  is  also 
recognized. The agents that can be used to protect normal 
cells thus have been already clinically tested. Another 
observation of clinical importance stems from the use 
of metformin. While metformin was shown to have the 
property to protect normal cells it also has antineoplastic 
activity against prostate,[9] breast [10] and other cancers 
[11]. Application of MF+RAPA, perhaps combined with 
fasting [12] or with 2-deoxyglucose [12] (2-DG) to reduce 
glucose utilization (2-DG is also well characterized for 
clinical use) may provide concurrently the protection of 
normal cells and the antineoplastic activity. 
The advantage of cyclotherapy stems from the fact that 
response of normal cells to the protective agents targeting 
their signaling and metabolic pathways, which are well 
characterized, is predictable. In contrast, targeting cancer 
is uncertain since many of the pathways, often different 
in various cancers, are dysfunctional. Furthermore, even 
personalized targeting, after identification of the defective 
pathways of a given cancer, may be inadequate because 
of changes that may occur due to tumor progression, in 
the time interval between tumor sampling and its full 
characterization.  
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